Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj.

Search

Menu

Close

PrijavaOdjava
Naši lijekoviTerapijska područjaMedia CentarMedia CentarDogađanjaMaterijaliVideo resursiKontaktirajte nasPovežimo seKontaktirajte nasMedicinske informacije tvrtke Pfizer

Informacije o prijavljivanju nuspojava mogu se pronaći na dnu stranice.

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Pneumococcal infections remain a leading cause of death in children under 5 years of age worldwide1,2Major manifestations of infection with Streptococcus pneumoniae1

Invasive pneumococcal disease (IPD)
Includes meningitis, bacteraemia/sepsis
Approximately 300,000 deaths among children <5 years of age were estimated to be caused by pneumococcal infections in 2015. Case fatality rates from IPD in children can be high, ranging up to 20% for septicaemia and 50% for meningitis in certain parts of the world.3

Pneumonia
Community-acquired pneumonia (CAP) is a leading cause of death worldwide in children under 5 years of age.4,5

Otitis media (OM)
S. pneumoniae accounts for 30% to 50% of all OM cases worldwide and is the most likely pathogen to be associated with recurrent infections and postinfectious complications characteristic of complicated OM.6

Prevenar 20™ helps prevent pneumococcal disease caused by the 20 serotypes in the vaccine, providing the broadest serotype coverage available in a pneumococcal conjugate vaccine.7-9
Explore the broadest serotype coverage available for babies7-9
LoadingReferences:Gierke R, Wodi AP, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Centers for Disease Control and Prevention; 2021:chap 17. Accessed March 29, 2023. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.UNICEF. Childhood diseases. Accessed February 15, 2022. https://www.unicef.org/health/childhood-diseases.World Health Organization. Weekly epidemiological record. Vol 8. 2019;94:85-104.Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020;96(suppl 1):29-38.Popovsky EY, Florin TA. Community-acquired pneumonia in childhood. Encyclopedia of Respiratory Medicine. 2nd ed. Elsevier; 2022:119-131.Bergenfelz C, Hakansson AP. Streptococcus pneumoniae otitis media pathogenesis and how it informs our understanding of vaccine strategies. Curr Otorhinolaryngol Rep. 2017;5(2):115-124.Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.AboutQuick links card The broadest serotype coverage for babies in a pneumococcal conjugate vaccine7-9 Learn more LoadingQuick links card [Local body] recommends Prevenar 20™ for routine infant vaccination10 Learn more Loading
PP-PNR-GLB-0425 March 2024

Ako želite prijaviti štetni događaj, molimo Vas pošaljite e-mail na adresu [email protected] ili nazovite broj 013908788. Za medicinske upite, molimo Vas pošaljite e-mail na adresu: [email protected] ili nazovite broj 013908777.

PfizerPro računPfizerPro račun

Za pristup daljnjim materijalima, resursima i primanje obavijesti o lijekovima i cjepivima tvrtke Pfizer

PrijavaRegistracijaRačunOdjava

SAMO ZA ZDRAVSTVENE RADNIKE

Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj. Ako ste član šire javnosti koji želi ostvariti pristup informacijama o određenom lijeku, molimo Vas obratite se Vašem liječniku ili ljekarniku. 

Ovu web stranicu Vam donosi Pfizer Croatia d.o.o.

Autorsko pravo 2022. Pfizer Croatia d.o.o. Sva prava pridržana.

PP-UNP-HRV-0139, datum izrade: kolovoz, 2023.
Napuštate PfizerPro
​
Sada napuštate internetsku stranicu kojom upravlja Pfizer. Poveznice koje vode svim vanjskim stranicama su dani kao resurs za naše posjetitelje. Pfizer ne prihvaća nikakvu odgovornost za sadržaj stranica koji nisu u vlasništvu i kojima Pfizer ne upravlja.

PP-UNP-HRV-0139
datum izrade: kolovoz, 2023.
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​